NSE: ANTHEM | BSE: 544449

Expensive Performer

Download real time

765.35 -11.75 (-1.51%)

423.4K NSE+BSE Volume

NSE 25 May, 2026 3:31 PM (IST)

43,104.1

Market Cap

High in industry

Dividend

Anthem Biosciences has an upcoming dividend of ₹2.000 per share due on 25 Jun 2026 See details

Anthem Biosciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ANTHEM, BSE:544449 Anthem Biosciences Ltd.

Search Inside the pdf :

Anthem Biosciences Ltd.

21 May 2026

765.35

-1.51%

Anthem Biosciences (BUY): Growth drivers intact; industry-leading margins to sustain

Buy: Anthem Biosciences Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT grew by 0.1%/6.9%/27% above our estimates. EBITDA margin 280 bps above our estimates, at 43.7%

Anthem Biosciences has gained 34.27% in the last 1 Year

Anthem Biosciences Ltd.

27 Feb 2026

765.35

-1.51%

[Initiation] Anthem Biosciences (BUY): Full-spectrum CRDMO capabilities

Buy: Anthem Biosciences Ltd.

BOB Capital Markets Ltd.

Being one of the few backward-integrated peptide manufacturers, gives it cost edge over China competitors in GLP

Anthem Biosciences has gained 34.27% in the last 1 Year

Anthem Biosciences Ltd.

14 Jul 2025

765.35

-1.51%

IPO Note

IPO Note: Anthem Biosciences Ltd.

Deven Choksey

Anthem Bioscience’s initial issue is priced at 47.4x TTM EV/EBITDA
compared to peer average of 42.7x TTM EV/EVITDA. Even though, the issue
seems to be priced higher than the peer average, we believe it demands a
premium led by stronger growth, industry leading margins, steady profitability
and deep capability to produce complex products. We assign a “SUBSCRIBE”
rating to the issue.

Anthem Biosciences has gained 34.27% in the last 1 Year

Anthem Biosciences Ltd.

12 Jul 2025

765.35

-1.51%

ANTHEM BIOSCIENCE

IPO Subscribe: Anthem Biosciences Ltd.

Hem Securities

manufacturing. Company is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery,...

BOB Capital Markets Ltd. increased Buy price target of Anthem Biosciences Ltd. to 900.0 on 21 May, 2026.

Anthem Biosciences Ltd.

11 Jul 2025

765.35

-1.51%

ANTHEM BIOSCIENCES LTD.

IPO Subscribe: Anthem Biosciences Ltd.

Ventura

IPO NOTE

Anthem Biosciences Ltd. is trading above all available SMAs

Anthem Biosciences Ltd.

10 Jul 2025

765.35

-1.51%

Anthem Biosciences Ltd IPO Note

IPO Subscribe: Anthem Biosciences Ltd.

SBI Securities

Anthem Biosciences Ltd. is a fast-growing innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering endto-end services across drug discovery, development and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). Serving global biotech and pharma companies, the company reached Rs 1,000 cr in revenue...